KIF1A

JULY 1, 2023

Taking a drug that shelved during development or didn’t receive FDA approval, and assessing its application for another disease, is called drug repositioning. It requires a deep look at former products that ended at various stages of research and development.

Small Molecule 98

Small Molecule FDA Approval Disease Pharmaceutical Companies 98

Drug Target Review

SEPTEMBER 19, 2023

The International Consortium for Innovation and Quality in Pharmaceutical Development has published guidelines to qualify as a valid model for specific organ-chip applications. These guidelines drive the legitimacy of the models towards regulatory approval.

Animal Testing 98

Animal Testing Clinical Trials Pharmaceutical Companies FDA 98

The Pharma Data

DECEMBER 16, 2020

–( BUSINESS WIRE )– ANI Pharmaceuticals, Inc. , (“ANI” or the “Company”) (Nasdaq: ANIP) today announced U.S. Food and Drug Administration (FDA) approval and the launch of Aminocaproic Acid Tablets USP, 500mg. ANI Pharmaceuticals, Inc. BAUDETTE, Minn.–( The current annual U.S. earlier this year.

Pharmaceuticals 40

Pharmaceuticals FDA Approval Production Pharmaceutical Companies 40

The Pharma Data

JULY 8, 2021

is a leading global pharmaceutical company headquartered in Japan. We routinely post information that may be important to investors on our website at www.biogen.com. Follow us on social media – Twitter , LinkedIn , Facebook , YouTube. About Eisai Co.,

Clinical Trials 52

Clinical Trials FDA Approval Trials FDA 52

The Pharma Data

JANUARY 6, 2021

UNION therapeutics A/S is a privately held, clinical stage, pharmaceutical company dedicated to the development of novel treatments for inflammatory and infectious diseases. The Company is working on two complementary chemistry classes spanning immunology and microbiology and has five candidates in clinical development.

FDA Approval 52

FDA Approval FDA Clinical Development Clinical Research 52

The Pharma Data

SEPTEMBER 23, 2020

It is also expected that they will require data for an emergency clearance which is nearly as extensive as the information needed for a general approval. . These new guidelines mean it will take extra time for pharmaceutical companies to prepare their applications and for the regulatory body to review the data. Conor Kavanagh.

Vaccine 52

Vaccine FDA FDA Approval Clinical Trials 52

The Pharma Data

MARCH 26, 2021

If approved, ponesimod will be the first therapy by Janssen for patients living with RMS with active disease defined by clinical or imaging features. Damage to myelin slows or halts nerve conduction, producing the neurologic signs and symptoms of MS. [8]. Adverse events should be reported.

Treatment 52

Treatment Pharmaceutical Companies Pharmaceuticals FDA Approval 52

Advarra

AUGUST 16, 2022

Food and Drug Administration (FDA) approval. Since then, the FDA has significantly changed its approach to rare and orphan diseases. The FDA Since 1983. The Orphan Drug Act of 1983 was instrumental in changing the number of orphan drugs approved in the U.S. Before 1983, only 38 orphan drugs had received U.S.

Disease 52

Disease Clinical Trials FDA Approval FDA 52

The Connected Lab

APRIL 8, 2020

For patients suffering from an illness with no approved treatment, the wait can be unnerving. To this day, more than 400 million people suffer from rare diseases and 95% of rare diseases lack an FDA approved treatment 3. Companies such as Celgene, GSK, Sanofi, and Sunovion have partnered with Exscientia to solve this problem.

Pharma Companies 52

Pharma Companies Laboratories Drugs FDA Approval 52

The Pharma Data

DECEMBER 28, 2020

29, 2020 (GLOBE NEWSWIRE) — Amphastar Pharmaceuticals, Inc. , (NASDAQ: AMPH) announced that the U.S. Food and Drug Administration (“FDA”) has approved its Abbreviated New Drug Application (“ANDA”) for Glucagon for Injection Emergency Kit, 1 mg. Company Information. Source: Amphastar Pharmaceuticals, Inc.

FDA 52

FDA Production Biosimilars FDA Approval 52

The Pharma Data

DECEMBER 28, 2020

Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Annamycin for treatment of soft tissue sarcomas. .

FDA 52

FDA Clinical Trials Drugs Pharmaceutical Companies 52

The Pharma Data

OCTOBER 29, 2020

Regeneron Pharmaceuticals, Inc. NASDAQ: REGN ) today announced that the company was once again ranked as the top company to work for by Science magazine in its annual Top Employers Survey of the global biotech and pharmaceutical industry. SOURCE Regeneron Pharmaceuticals, Inc. Schleifer , M.D., Source link.

Science 40

Science FDA Approval Pharmaceuticals Disease 40

The Pharma Data

JUNE 28, 2021

There are currently no FDA-approved anticoagulation therapies for pediatric patients with congenital heart disease who have undergone the Fontan procedure. by Janssen Pharmaceuticals, Inc. Janssen Research & Development, LLC and Janssen Pharmaceuticals, Inc. Xarelto is marketed outside the U.S.

FDA 52

FDA Clinical Trials Treatment Therapies 52

The Pharma Data

JANUARY 13, 2021

Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, today announced that it has priced an underwritten public offering of 5,000,000 shares of its common stock at a price to the public of $2.50 SOLANA BEACH, Calif., 13, 2021 (GLOBE NEWSWIRE) — Evoke Pharma, Inc.

Pharmaceutical Companies 40

Pharmaceutical Companies FDA Approval Clinical Trials Pharmaceuticals 40

The Pharma Data

DECEMBER 8, 2020

The fully integrated pharmaceutical company creates value through China’s specialty pharmaceutical markets with focus on iron deficiency, pain management and respiratory. The company’s goal is focused on improving outcomes for cancer patients by harnessing the power of targeted radioisotopes. SciNeuro Pharmaceuticals .

RNA 52

RNA Therapies Disease Protein Expression 52

The Pharma Data

JANUARY 5, 2021

based contract manufacturing business, Benuvia Manufacturing, which has significant chemistry and formulation capabilities, including manufacturing our FDA-approved cannabinoid drug, SYNDROS ® ,” said Todd C. We look forward to supporting Radius through our U.S. Davis, executive chairman of Benuvia. Disease Highlights.

Disease 52

Disease FDA Approval Clinical Trials Trials 52

The Pharma Data

NOVEMBER 5, 2020

05, 2020 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today reported its financial results for the quarter ended September 30, 2020 and provided a corporate update. FDA approval, and customary exceptions).

Pharmaceuticals 52

Pharmaceuticals Production Marketing Pharmaceutical Companies 52

The Pharma Data

DECEMBER 1, 2020

“Since founding the bio fund at Andreessen Horowitz, our mandate has been to help launch companies at the intersection of computer science and biology to change the face of the healthcare and pharmaceutical industries,” said Dr. Pande. “It

Engineering 40

Engineering FDA Approval Drugs Pharmaceuticals 40

The Pharma Data

AUGUST 19, 2021

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced preliminary data from the Phase 1 CHRYSALIS study evaluating RYBREVANT TM (amivantamab-vmjw) for the treatment of patients with non-small cell lung cancer (NSCLC) with mesenchymal-epithelial transition (MET) exon 14 skipping (METex14) mutations.

Treatment 52

Treatment FDA Approval Pharmacokinetics FDA 52

The Pharma Data

OCTOBER 21, 2020

The complete regimen combines the integrase strand transfer inhibitor (INSTI) cabotegravir, developed by ViiV Healthcare, with rilpivirine, a non-nucleoside reverse transcriptase inhibitor (NNRTI) developed by Janssen Sciences Ireland UC, part of the Janssen Pharmaceutical Companies of Johnson & Johnson. Source: GSK .

Clinical Development 52

Clinical Development Therapies Clinical Trials Treatment 52

DrugBank

FEBRUARY 12, 2025

The pharmaceutical industry grapples with the persistent challenge of high attrition rates and escalating costs inherent in drug development. The National Institutes of Health (NIH) Clinical Collection , a library of FDA-approved drugs, is widely used for HTS in drug repurposing initiatives.

Cell Based Assays 52

Cell Based Assays Drugs Pharmacokinetics Disease 52

Drug Target Review

AUGUST 3, 2023

We use FDA-approved and CE-marked DNA collection devices that have been proved and tested as the gold standard in saliva-based DNA collection devices and are widely used by pharmaceutical companies and research institutions worldwide.

DNA 52

DNA Clinical Trials Trials Disease 52

Advarra

JULY 19, 2022

The sponsor is the pharmaceutical company conducting the trial. A: Working in a pharmaceutical company is the best way to learn this. Each company will have its own processes, but they will all have the same result. The sponsor-initiated IND is conducted by a pharma company seeking commercial approval.

Packaging 52

Packaging FDA Trials Regulations 52

The Pharma Data

JANUARY 17, 2021

Guardant360 ® tests are used by oncologists around the world to guide treatment decisions across solid tumor cancers, and by pharmaceutical companies and academic researchers in clinical trials to accelerate precision medicine drug development. Guardant Health has achieved CE mark approval as well as U.S.

Clinical Trials 40

Clinical Trials FDA Approval Treatment Trials 40

The Pharma Data

NOVEMBER 30, 2020

1, 2020 /PRNewswire/ — Sosei Group Corporation (“the Company”) (TSE: 4565) announces it has entered into a global collaboration and license agreement with Biohaven Pharmaceutical Holding Company Ltd. (“Biohaven”, NYSE: BHVN). NURTEC is a trademark of Biohaven Pharmaceutical Ireland DAC.

Small Molecule 40

Small Molecule Licensing Licensing Treatment 40

Practical Cheminformatics

AUGUST 3, 2023

Most pharmaceutical compounds tend to have solubilities somewhere between 1 and 500 µM. Clintox – This dataset consists of 1483 SMILES strings and two binary labels indicating whether a molecule is an FDA-approved drug and whether a toxicity outcome has been reported. Values less than 1µM are often reported as “ 500µM”.

Drugs 84

Drugs Biochemical Assays Metabolic Stability Screening Hits 84

The Pharma Data

DECEMBER 29, 2020

Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx ®. Protalix was the first company to gain FDA approval of a protein produced through plant cell-based in suspension expression system.

Clinical Trials 52

Clinical Trials Disease Treatment Trials 52

The Pharma Data

JANUARY 21, 2021

21, 2021 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. About the Janssen Pharmaceutical Companies of Johnson & Johnson At Janssen, we’re creating a future where disease is a thing of the past. US Approval January 2021. TITUSVILLE, N.J. ,

FDA Approval 52

FDA Approval Treatment RNA FDA 52

The Pharma Data

JANUARY 17, 2021

18 , 2021 /PRNewswire/ — Hanmi Pharmaceutical Co., In particular, two new drugs developed by Hanmi Pharmaceutical Co., are expected to be approved by the U.S. . In particular, two new drugs developed by Hanmi Pharmaceutical Co., are expected to be approved by the U.S.

FDA Approval 52

FDA Approval FDA Pharmaceuticals Clinical Trials 52

The Pharma Data

NOVEMBER 8, 2020

FDA Approves Sesquient (fosphenytoin sodium) for the Treatment of Status Epilepticus in Adult and Pediatric Patients. PAOLI, Pa., — (BUSINESS WIRE) — November 9, 2020 – Sedor Pharmaceuticals, LLC (Sedor) today announced that the U.S. About Sedor Pharmaceuticals, LLC. About Sesquient.

FDA Approval 52

FDA Approval FDA Long-Term Care Facilities Treatment 52

The Pharma Data

OCTOBER 14, 2020

14, 2020 /PRNewswire/ — Harmony Biosciences Holdings, Inc. (“Harmony”) (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced the U.S. PLYMOUTH MEETING, Pa.

FDA Approval 40

FDA Approval FDA Treatment Clinical Trials 40

The Pharma Data

FEBRUARY 25, 2022

Jardiance is the first and only heart failure therapy to demonstrate a statistically significant risk reduction in cardiovascular death or hospitalization for heart failure, regardless of ejection fraction FDA approval marks a significant breakthrough for the approximately 3 million adults in the U.S. and Europe.

FDA Approval 52

FDA Approval FDA Hospitals Clinical Trials 52

The Pharma Data

DECEMBER 16, 2020

–( BUSINESS WIRE )– Aurinia Pharmaceuticals Inc. NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”) today announced it has entered into a collaboration and license agreement with Otsuka Pharmaceutical Co., Makoto Inoue, President and Representative Director of Otsuka Pharmaceutical Co., 17, 2020 09:00 UTC.

Licensing 52

Licensing Licensing Pharmaceuticals Disease 52

The Pharma Data

SEPTEMBER 1, 2021

Approval is backed by nearly two decades of proven efficacy and safety of Janssen’s long-acting injectable portfolio of schizophrenia medicines. The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S.

FDA Approval 52

FDA Approval FDA Treatment Clinical Trials 52

The Pharma Data

APRIL 27, 2021

Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced that that the U.S. About Takeda Pharmaceutical Company Limited. Mobocertinib is the first oral therapy specifically designed to selectively target EGFR Exon20 insertion mutations. ryoko.matsumoto@takeda.com . +81

FDA 52

FDA Treatment Pharmaceutical Companies Therapies 52

The Pharma Data

OCTOBER 20, 2020

–( BUSINESS WIRE )– Mycovia Pharmaceuticals, Inc. Oteseconazole received FDA Qualified Infectious Disease Product Status and Fast-Track designation with NDA submission planned for 1H 2021. About Mycovia Pharmaceuticals. 21, 2020 15:50 UTC. Top-line Data Remains on Track for Late 2020. DURHAM, N.C.–(

Treatment 52

Treatment Pharmaceuticals Clinical Trials FDA Approval 52

The Pharma Data

OCTOBER 9, 2021

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. About the Janssen Pharmaceutical Companies of Johnson & Johnson At Janssen, we’re creating a future where disease is a thing of the past.

FDA Approval 52

FDA Approval Treatment FDA Pharmaceutical Companies 52